About CuroVax
发展历程
2022
Establishment of a wholly-owned subsidiary, "Runtaiyi".
2021
NDA submission for "Lyophilised Human Rabies Vaccine (Vero Cell)" project was accepted. The project of "Tetravalent Influenza Virus Lysate Vaccine" was approved for clinical trial.
2019
Establishment of the project "Tetravalent Influenza Virus Lysing Vaccine".
2017
"Completion of Phase III Clinical Trial of Lyophilised Human Rabies Vaccine (Vero Cell) Project
2014
The project "Lyophilised Human Rabies Vaccine (Vero Cell)" obtained clinical trial approval.
2013
Received GMP certificate for "Influenza virus lysate vaccine" project.
2011
Establishment of CuroVax by Kangrun Bio
